TW585766B - Combination of active ingredients for the treatment of senile dementia of the Alzheimer type - Google Patents

Combination of active ingredients for the treatment of senile dementia of the Alzheimer type Download PDF

Info

Publication number
TW585766B
TW585766B TW087117874A TW87117874A TW585766B TW 585766 B TW585766 B TW 585766B TW 087117874 A TW087117874 A TW 087117874A TW 87117874 A TW87117874 A TW 87117874A TW 585766 B TW585766 B TW 585766B
Authority
TW
Taiwan
Prior art keywords
tetrahydropyridine
alkyl
ethyl
trifluoromethylphenyl
biphenyl
Prior art date
Application number
TW087117874A
Other languages
English (en)
Chinese (zh)
Inventor
Jean-Pierre Maffrand
Philippe Soubrie
Jean-Paul Terranova
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of TW585766B publication Critical patent/TW585766B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW087117874A 1997-11-14 1998-10-28 Combination of active ingredients for the treatment of senile dementia of the Alzheimer type TW585766B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
TW585766B true TW585766B (en) 2004-05-01

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087117874A TW585766B (en) 1997-11-14 1998-10-28 Combination of active ingredients for the treatment of senile dementia of the Alzheimer type

Country Status (27)

Country Link
EP (1) EP1030671A1 (ko)
JP (1) JP2001523642A (ko)
KR (1) KR100599350B1 (ko)
CN (1) CN1243540C (ko)
AU (1) AU743228B2 (ko)
BG (1) BG64819B1 (ko)
BR (1) BR9814035A (ko)
CA (1) CA2309966A1 (ko)
CO (1) CO4980891A1 (ko)
DZ (1) DZ2649A1 (ko)
EA (1) EA003255B1 (ko)
EE (1) EE04235B1 (ko)
HU (1) HUP0100098A3 (ko)
ID (1) ID24933A (ko)
IL (2) IL136122A0 (ko)
IS (1) IS5482A (ko)
MY (1) MY120461A (ko)
NO (1) NO20002450L (ko)
NZ (1) NZ504420A (ko)
OA (1) OA11464A (ko)
PL (1) PL194597B1 (ko)
SA (1) SA98190747B1 (ko)
SK (1) SK286040B6 (ko)
TR (1) TR200001262T2 (ko)
TW (1) TW585766B (ko)
UY (1) UY25247A1 (ko)
WO (1) WO1999025363A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100375619C (zh) * 2002-06-14 2008-03-19 富山化学工业株式会社 改善脑功能的药物组合物及其用途
PT1529116E (pt) * 2002-08-07 2009-09-10 Novartis Ag Métodos para o tratamento da demência com base no genótipo da apo e
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
JP2008525313A (ja) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
DK3498692T3 (da) 2014-01-31 2022-05-16 Cognition Therapeutics Inc Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration
BR112019023851A2 (pt) * 2017-05-15 2020-08-18 Cognition Therapeutics, Inc. compostos, suas composições farmacêuticas e métodos para tratamento de doenças neurodegenerativas
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
KR102224917B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
CN1126546C (zh) * 1995-03-06 2003-11-05 英特纽隆制剂药有限公司 使用胞磷胆碱减少梗塞面积
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
HUP0100098A3 (en) 2001-12-28
EE04235B1 (et) 2004-02-16
KR20010032099A (ko) 2001-04-16
NZ504420A (en) 2003-08-29
PL194597B1 (pl) 2007-06-29
CN1285742A (zh) 2001-02-28
CO4980891A1 (es) 2000-11-27
EE200000290A (et) 2001-06-15
ID24933A (id) 2000-08-31
JP2001523642A (ja) 2001-11-27
NO20002450D0 (no) 2000-05-11
OA11464A (en) 2003-11-18
TR200001262T2 (tr) 2001-01-22
CA2309966A1 (en) 1999-05-27
PL340500A1 (en) 2001-02-12
AU1160999A (en) 1999-06-07
SK7112000A3 (en) 2000-10-09
IL136122A (en) 2006-07-05
NO20002450L (no) 2000-07-14
IS5482A (is) 2000-05-09
EP1030671A1 (fr) 2000-08-30
CN1243540C (zh) 2006-03-01
SA98190747B1 (ar) 2006-11-04
BR9814035A (pt) 2000-09-26
IL136122A0 (en) 2001-05-20
HUP0100098A2 (hu) 2001-07-30
AU743228B2 (en) 2002-01-24
DZ2649A1 (fr) 2004-12-28
EA200000412A1 (ru) 2000-12-25
BG104428A (en) 2001-08-31
UY25247A1 (es) 2001-05-31
SK286040B6 (sk) 2008-01-07
BG64819B1 (bg) 2006-05-31
KR100599350B1 (ko) 2006-07-12
EA003255B1 (ru) 2003-02-27
WO1999025363A1 (fr) 1999-05-27
MY120461A (en) 2005-10-31

Similar Documents

Publication Publication Date Title
CA2282654C (en) Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
TW201028147A (en) Dosage regimen of an S1P receptor agonist
EP3265087B1 (en) Method of treatment with tradipitant
CA2582436C (en) Combinations of nicotinic acetylcholine alpha 7 receptor agonists
WO2013029762A1 (en) Morphinan-derivatives for treating diabetes and related disorders
AU2006251893A1 (en) Scopolamine for the treatment of depression and anxiety
TW585766B (en) Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
NZ539711A (en) Solid preparation
WO1995007690A1 (en) Composition and method for treating nicotine craving in smoking cessation
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
TW517048B (en) Pharmaceutical composition for treating depressive disorders and bipolardisorders comprising (+)-Α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
AU2016218950C1 (en) Analgesic formulation
US20080125442A1 (en) Cathepsin K Inhibitors and Atherosclerosis
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
HU206829B (en) Process for producing pharmaceutical compositions containing buspirone against smoking and obesity
KR20010024768A (ko) 혈관성 두통에 대한 국소 마취제의 신규 용도
JP2003503459A (ja) パラセタモール及びブスピロンを含有した鎮痛性作用を有する新規医薬組成物
JP2001511159A (ja) オキシムを含むシナプス機能障害の処置用医薬組成物
CN110167553A (zh) 新颖的剂量方案
EP1524982B1 (de) Medikament und verfahren zur verringerung des alkohol-und/oder tabakkonsums
CZ20001734A3 (cs) Farmaceutická kompozice a její použití
MXPA00004600A (en) Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
CN116236559A (zh) 眼镜蛇科蛇突触后神经毒素单体分子在治疗药物及酒精依赖或戒断症状上的应用
WO1988007867A1 (en) Nootropic
WO2002051416A1 (fr) Medicaments ameliorant les comportements de la vie courante chez des personnes atteintes de la maladie d'alzheimer

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees